At LogiPharma USA 2026, Mark Talens explains where pharma gains the most from shared distribution visibility.

Freehand CEO Nitin Jayakrishnan explains why pharma manufacturers are trading long-term plans for operating models built to sense and pivot.

At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how onshoring, geopolitical risk and a shifting product mix are driving supply chain automation.

At LogiPharma USA 2026, quality leaders explained why connected data, risk-based prioritization, and human accountability must come before AI in supply chain compliance.

Swisslog's Mark Beers discusses how software helps pharma supply chains adapt to shifting portfolios, strengthen inventory verification and build trust.

McKesson's Chris Van Norman previews his LogiPharma USA keynote on demand signal sharing, AI, and precision distribution for targeted therapies.

Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.

Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.